Advertisement

Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry

      Highlights

      • The optimal therapy of VTE in patients with glioblastoma multiforme is unknown.
      • They had a higher rate of recurrent PE and major bleeding than those without cancer.
      • Their outcome was similar to that in patients with other cancers.

      Abstract

      Background

      There is uncertainty about the optimal therapy of venous thromboembolism (VTE) in patients with glioblastoma multiforme (GBM).

      Methods

      We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of VTE recurrences and major bleeding during the course of anticoagulation in patients with GBM, other cancers and in patients without cancer.

      Results

      As of September 2014, 53,546 patients have been recruited in RIETE. Of these, 72 (0.13%) had GBM and 11,811 (22%) had other cancers. Most patients in all 3 subgroups received initial therapy with low-molecular-weight heparin (LMWH), but those with GBM received slightly lower doses than those with other cancers or without cancer. Then, most patients with GBM continued on LMWH for long-term therapy, at similar doses than those in the other subgroups. During the course of anticoagulation (mean, 202 days), 3 patients with GBM presented VTE recurrences (10.9 per 100 patient-years; 95% CI: 2.76–29.5) and 4 suffered major bleeding (one intracranial) (14.5 bleeds per 100 patient-years; 95%CI: 4.60–34.9). Compared with patients with other cancers, those with GBM had a similar rate of VTE recurrences and major bleeds, but had a higher rate of extracranial hematoma (p < 0.05). Compared with VTE patients without cancer, those with GBM had a higher rate of PE recurrences (p < 0.01) and major bleeding (p < 0.001), particularly extracranial hematoma (p < 0.001).

      Conclusions

      Patients with GBM and VTE had a similar rate of VTE recurrences or major bleeds during the course of anticoagulant therapy than those with other cancers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Walker A.J.
        • Card T.R.
        • West J.
        • Crooks C.
        • Grainge M.J.
        Incidence of venous thromboembolism in patients with cancer. A cohort study using linked United Kingdom databases.
        Eur. J. Cancer. 2013; 49: 1404-1413
        • Petterson T.M.
        • Marks R.S.
        • Ashrani A.A.
        • Bailey K.R.
        • Heit J.
        Risk of site-specific cancer in incident venous thromboembolism: a population-based study.
        Thromb. Res. 2015; 135: 472-478
        • Perry J.R.
        Thromboembolic disease in patients with high-grade glioma.
        Neuro-Oncology. 2012; : iv73-iv80
        • Patel D.
        • Salkeni M.
        • Chaudhary R.
        Bevacizumab and glioblastoma multiforme: a thrombosis and bleeding dilemma (a case report and a brief review of the literature).
        Am. J. Ther. 2013; (Epub ahead of print)
        • Pabinger I.
        • Thaler J.
        • Ay C.
        Biomarkers for prediction of venous thromboembolism in cancer.
        Blood. 2013; 122: 2011-2018
        • Magnus N.
        • D'Asti E.
        • Garnier D.
        • Meehan B.
        • Rak J.
        Brain neoplasms and coagulation.
        Semin. Thromb. Hemost. 2013; 39: 881-895
        • Rahman R.
        • Catalano P.J.
        • Reardon D.A.
        • Norden A.D.
        • Wen P.Y.
        • Lee E.Q.
        • et al.
        Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation.
        J. Neuro-Oncol. 2015; 124: 137-146
        • Yust-Katz S.
        • Mandel J.J.
        • Wu J.
        • Yuan Y.
        • Webre C.
        • Pawar T.A.
        • et al.
        Venous thromboembolism (VTE) and glioblastoma.
        J. Neuro-Oncol. 2015; 124: 87-94
        • Strowd R.E.
        • Knovich M.A.
        • Lesser G.J.
        The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies.
        Curr. Treat. Options in Oncol. 2012; 13: 451-464
        • Trujillo-Santos J.
        • Herrera S.
        • Page M.A.
        • Soto M.J.
        • Raventós A.
        • Sánchez R.
        • Monreal M.
        Predicting adverse outcome in outpatients with acute deep vein thrombosis. Findings from the RIETE registry.
        J. Vasc. Surg. 2006; 44: 789-793
        • Ruíz-Giménez N.
        • Suárez C.
        • González R.
        • Nieto J.A.
        • Todolí J.A.
        • Samperiz A.L.
        • Monreal M.
        Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE registry.
        Thromb. Haemost. 2008; 100: 26-31
        • Nieto J.A.
        • Solano R.
        • Ruiz-Ribó M.D.
        • Ruiz-Giménez N.
        • Prandoni P.
        • Kearon C.
        • Monreal M.
        Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry.
        J. Thromb. Haemost. 2010; 8: 1216-1222
        • Sánchez Muñoz-Torrero J.F.
        • Bounameaux H.
        • Pedrajas J.M.
        • Lorenzo A.
        • Rubio S.
        • Kearon C.
        • et al.
        Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis.
        J. Vasc. Surg. 2011; 54: 26S-32S
        • Muriel A.
        • Jiménez D.
        • Aujesky D.
        • Bertoletti L.
        • Decousus H.
        • Laporte S.
        • et al.
        Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk.
        J. Am. Coll. Cardiol. 2014; 63: 1675-1683
        • Lecumberri R.
        • Alfonso A.
        • Jiménez D.
        • Fernández-Capitán C.
        • Prandoni P.
        • Wells P.S.
        • et al.
        Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.
        J. Thromb. Haemost. 2013; 110: 834-843
        • Cote L.P.
        • Greenberg S.
        • Caprini J.A.
        • Stone J.
        • Arcelus J.I.
        • López-Jiménez L.
        • et al.
        Outcomes in neurosurgical patients who develop venous thromboembolism: a review of the RIETE registry.
        Clin. Appl. Thromb. Hemost. 2014; 20: 772-778
        • Farge D.
        • Trujillo-Santos J.
        • Debourdeau P.
        • Bura-Rivière A.
        • Rodriguez-Beltrán E.M.
        • Nieto J.A.
        • et al.
        Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism.
        Medicine (Baltimore). 2015; 94e1235